Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)

Abstract Background Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. Several clinical trials have shown that local ablative therapy (LAT) at all sites of the disease might be beneficial for patient...

Full description

Bibliographic Details
Main Authors: Taichi Miyawaki, Hirotsugu Kenmotsu, Hideyuki Harada, Yasuhisa Ohde, Yasutaka Chiba, Koji Haratani, Tamio Okimoto, Tomohiro Sakamoto, Kazushige Wakuda, Kentaro Ito, Takehiro Uemura, Shinya Sakata, Yoshihito Kogure, Yasumasa Nishimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Format: Article
Language:English
Published: BMC 2021-10-01
Series:BMC Cancer
Subjects:
Clinical trial
Programmed cell death 1 inhibitor
Oligometastatic disease
Local ablative therapy
Progression-free survival
Online Access:https://doi.org/10.1186/s12885-021-08851-z

Internet

https://doi.org/10.1186/s12885-021-08851-z

Similar Items